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posttransplant lympboproliferative disorders (PTLDs) 
.ere diagnosed in 43 patients from the Pittsburgh-
Denver series between June 1980 and March 1987. This 
constitutes a detection rate of 1.7%. Major categories 
of clinical presentation included a mononudeosislike 
syndrome. gastrointestinal/abdominal disease. and 
solid organ disease. The median time of onset in pa-
tients initially immnnosuppressed with cydosporine-
A (CsA)-containing regimens was 4.4 montbs after 
U3nsplant, regardless of tumor c1onality. A strong as-
sociation ofPTLD with Epstein-Barr virus (EBV) was 
observed. A histologic spectrum of lesions from poly-
morphic to monomorphic was observed. Whereas 
polymorphic lesions could be either donal or non-
clonal, monomorphic lesions appeared to be clonal in 
(om position. The presence oflarge atypical cells (atyp-
ical immunoblasts) or necrosis did not appreciably 
-\:-J INCREASED INCIDENCE of lymphoprolifer-
alive disorders in immunosuppressed organ trans-
plant recipients is well established. l -6 These tumors 
most commonly are ofB cell origin and are associated 
\\'ith active infection by the Epstein-Barr virus 
J fEBV).7-15 The lesions may be clonal (monoclonal or 
multiclonal) or nondonal (polyclonal) and in many 
instances they will undergo regression ifimmunosup-
pression is reduced.8. 12•16-18 
This report analyzes clinicopathologic features 
of posttransplant lymphoproliferative disorders 
(PTLDs) arising in the patient series from the Univer-
sity of Pittsburgh. The population is composed of 
liver, kidney, heart.. and heart/lung recipients who re-
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worsen the prognosis. Twelve patients had donal, 13 
had nondonal, and five had both donal and non donal 
tumon. Clonality was indeterminate in 13 cases. Most 
patients were treated with a regimen based on reduced 
immunosuppression and supportive surgery. Almost 
all nondonal and about half of the donal lesions re-
spond to this conservative therapy, indicatiDg that it 
is an appropriate first line of treatment. This behavior 
suggests that a spectrum oflesions rangiDg from infec-
tious mononucleosis to malignant lymphoma consti-
tutes the entity known as PTLD. Some monoclonal tu-
mors can undergo regressioD. however, apparently in 
response to host immune control mechanisms. Because 
of its short latency and strong association with EBV. 
PTLD is an important model for the study of virus-
associated tumor progression in humans. (AmJ Pathol 
1988,133:173-192) 
ceived immunosuppressive regimens that included 
cyclosporine-A (CsA). The present study allows a 
more comprehensive picture of CsA-associated lym-
phoproliferations than can be afforded by reports lim-
ited to tumors arising in association with specific or-
gan allografts (ie, heart)S.19.20 or in patients receiving 
non-CsA-containing immunosuppression.7.9.11.12.21 
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Materials and Methods 
Patient Population 
Organ transplants were performed at the University 
of Pittsburgh (1981-1987) or at the University of Col-
orado (1981 and earlier). The study population con-
sists of all patients from this transplant series who re-
ceived a pathologic diagnosis of either lymphoma or 
posttransplant Iymphoproliferative disorder (PTLD) 
between June 1980 and March 1987. Microscopic fea-
tures of the latte~ are discussed below. 
A total of 43 patients received these diagnoses dur-
ing this period. One patient who was originally in-
cluded in this category (No.8) was subsequently 
determined to have Hodgkin's disease and is not 
included in this series. In six cases (No. 19, 38, 39, 
41-43), adequate tissue for further analysis was un-
available. The inclusion of these latter six cases in this 
series is based on the descriptions provided in the orig-
inal pathology reports. Although these cases are in-
cluded in population statistics they are excluded from 
pathologic studies. 
Histologic: Evaluation 
Formalin-fixed, paraffin-embedded histologic sec-
tions from 37 patients were available for review. Sec-
tions were evaluated for degree of polymorphism, ne-
crosis, plasmacytic differentiation, and number of 
large atypical cells ("atypical immunoblasts,,). 7 Poly-
morphism refers to the presence of lymphoid cells in 
various stages of differentiation and not to the pres-
ence or absence of nonlymphoid cell types. A grade of 
o was given for the absence of polymorphism. Some 
cases showed minimal polymorphism in association 
with plasmacellular differentiation. These cases were 
graded as ). Other cases showed a wide range of lym-
phocyte forms. These cases received a polymorphism 
grade of 2. Necrosis was graded as 0 for absent, 1 if 
involving <10% of tissue, 2 for 10-25%, and 3 for 
> 25% involvement. Plasmacytic differentiation was 
graded as 0 for minimal to absent, 1 for mild, and 2 
for moderate to marked. The predominant cell type 
in this latter category was classified as plasmacytic or 
plasmacytoid. A plasmacytic cell, with mature eccen-
tric nucleus, is distinguishable from a plasmacytoid 
cell, which has an eccentric but less mature nucleus. 
The term atypical immunoblast refers to large mono-
nuclear cells with vesicular nuclei, irregular nuclear 
membranes, and prominent nucleoli. These cells have 
been described in both PTLDs and infectious mono-
nucleosis. 7.22 Atypical immunoblasts were graded as 0 
-
f 
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for absent, I for rare. and 2 for occasional. and 3 for:; 
frequent. ., 
Immunocytochemical Studies 
Analysis of cytoplasmic immunoglobulins was per. 
formed on paraffin-embedded tissues in 32 cases using 
the avidin-biotin peroxidase technique ofHsu with or 
without pronase digestion,23 or with the peroxidase_ 
antiperoxidase technique. Color was developed with 
0.05% diaminobenzidine (DAB) using light micros-
copy to titrate the stain. Slides were counterstainect 
with hematoxylin. Anti-kappa and anti-lambda anti-
sera were purchased from Dako Inc. CytOplasmic 
kappa:lambda light chain ratios were calculated on 
the basis of a count of200 mononuclear cells per slide. 
A kappa:iambda ratio of 5: I or greater was considered 
indicative of a monoclonal kappa component. Con- . 
versely, a lambda:kappa ratio of 3: I or greater was in-
terpreted as evidence for a monoclonal lambda prolif. 
eration.s 
In specimens from nine patients frozen sections 
were stained using the immunoperoxidase technique 
without digestion and with 3-amino-9-ethylcarbazole 
or DAB as the visualizing reagent. Frozen tissue im-
munofluorescence staining for immunoglobulin light 
chains was perfonned in selected specimens from six 
cases and used goat F(ab')2 fragments (Tago) follOwed 
by rhodamine-conjugated rabbit F(ab')2 anti-goat 
IgG. Reagents were ultracentrifuged before use to re-
move immune aggregates. Slides were read in a Leitz 
Laborlux microscope with epifluorescence attach-
ment. Primary antibody was replaced by diluent to 
serve as a negative control and appropriate positive 
biologic controls (plasmacytomas, tonsils) were in-
cluded in each batch of stains. Similar techniques 
were employed for those cases stained at St. Mary's 
Hospital, London (KP). 
Immunoglobulin Gene Rearrangement Studies 
Recombinant DNAs containing segments of the 
immunoglobulin heavy chain joining region (Jh), a 
heavy chain constant region (CIl), and light chain con· 
stant regions (Ckappa and Clambda), were obtained 
from Dr. Philip Leder, Harvard University.24 Purifi-
cation of high molecular weight DNA, restriction en-
zyme analyses; and Southern blot analyses were per-
formed on specimens from 20 patients according to 
protocols described previously.25 Frozen tissue sec-
tions were pulverized in dry ice, freeze-dried, and sol-
ubilized in standard lysing solution before regular pu-
rification procedures. This protocol is modified from 
Jdies 
.-1))' ~o I 
described by Graham et al. 26 All tumors were 
thJ1'ed with JH (BamHI) and Clambda (EcoRI) 
~udD and most were also studied with Ckappa 
~fF and CJ.l (BamHI) probes. Many were studied 
(83 additional enzymes. In all of the tumors where a 
.llh rearrangement was detected with any probe. JH 
1'0(1 .s using BamHI was positive and provided a 
,na ,SI . 
. sensiti ve detectIOn. D~;"e specimens were also analyzed for rearrange-
IS of immunoglobulin gene regions by Drs. M. 
~ry and J. Sklar. as de~ribed previously.17 
ESV studies 
The determination of primary, reactivation, or re-
ote EBV infection was based on specific EBV indi-~ immunofluorescen~e serologic tests. for titers of 
I M anti-VCA, IgG antl-VCA, IgG antl-EA (D and 
:, and anticomplement anti-EBNA in pretransplan-
IJI;On and posttransplantation samples as previously 
fl"POrted. 13 Primary infections were those in which a 
negative pretransplant IgG anti-VCA converted to 
positive after allograft. Reactivation or secondary in-
fections were diagnosed when preexistent IgG anti-
vC A titers rose more than four- fold after transplanta-
!Jon. 
Some specimens have been analyzed previously for 
EBV DNA by either J. Pagano, MD (University of 
Sorth Carolina), G. Miller, MD (Yale University), or 
J. Sklar. MD, PhD (Stanford University).13 
£\aluation of Tumor Response to Therapy 
A variety of therapeutic interventions were applied 
to patients with PTLDs over the time span of this ret-
rospective study. In addition, the courses of many 
patients were complicated by opportunistic infec-
tions, delayed diagnoses, and/or anecdotal changes in 
therapy. 
The categorization system employed in this report 
takes into account these confounding variables so as 
to provide. in as unbiased a manner as possible, an 
accurate statement of tumor behavior. 
The term "regression" is applied to those cases that 
demonstrated clinical or pathologic reduction and 
eventual disappearance of tumor mass in response 
to reduced immunosuppression, with or without 
acyclovir. Surgical intervention was limited to biopsy 
procedures of the tumor under investigation. Surgical 
resection of all grossly evident tumor precluded inclu-
sion into this category. Patients who received chemo-
therapy or radiation therapy were also excluded from 
this category. 
CsA TRA:-';SPLA:".i ivMmel~tAp 175 
The term "resolution" is used to represent cases in 
which tumor disappeared in the face of more aggres-
sive intervention. Because the possibility exists that 
this intervention (eg, total surgical resection, chemo-
therapy, radiotherapy) effectively eradicated the tu-
mor, a case for spontaneous regression cannot be 
made. It must be emphasized that placement ofa case 
into this category does not imply that the lesion was 
incapable of regression. Rather, it serves to recognize 
the limitations of retrospective analysis. 
Cases categorized as having had "no response" 
demonstrated clinical progression in spite of all mea-
sures taken. In contrast, cases with "no evaluable re-
sponse" had an ambiguous clinical course in which, 
for a variety of reasons, no evaluation of tumor beha v-
ior was possible. 
Rare cases had "partial resolution," implying that 
an ongoing response of tumor to therapy was appar-
ent. Death occurred from unrelated causes, prohibit-
ing the further expression of tumor behavior in this 
group of patients. 
Patients with "recurrence" showed evidence of re-
current tumor occurring some time after primary 
therapy. 
Finally, patients in the "autopsy" category had the 
diagnosis ofPTLD first made at autopsy. 
Tables 1-5 are arranged according to these catego-
ries, in order to present a clearer exposition of data. 
Results 
Patient Population and Tumor Incidence (Table 1) 
The patient population includes 29 men and 14 
women (M:F ratio, 2.1: 1). Ages at transplant range 
from 1-62 years with a mean age of 23.1 ± 2.7 years. 
Eighteen patients were 18 years of age or less at trans-
plant, and the remaining 25 were over 18 years old. 
The M:F ratio in the pediatric group ( < 18) was 1.6: 1, 
and in the adult group, 2.7: I. 
There are a total of23 liver, 12 kidney, 5 heart, and 
3 heart/lung patients in this study. This corresponds 
to a relative frequency of 1.0% for kidney, 2.2% for 
liver, 1.8% for heart, and 4.6% for heart/lung trans-
plants. The mean age of the liver allograft subpopula-
tion is 15.2 ± 3.2 years, which is lower than that of the 
other organ transplant groups. This statistic reflects 
the large number of pediatric liver patients treated at 
our institution. 
The yearly incidence of transplant patients who 
went on to develop lymphoproliferative disorders 
ranged from 1.4% in 1984 to 3.6% in 1982. The over-
all recognized frequency of PTLD development is 
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Tal:*! 1 -Posttransplant Lymphoproliferative Disorder: Patient Population 
Patient Response of tumor Transpjant Months to Months to Follow-up 
no. to therapy· Sex Age Organ date tumor recurrence (months) 
1 Regression M 44 Hear1 1120183 2.9 17.9 
2 RegresslOO F 28 Heart/lung 11/3/86 22 133 
3 RegresslOO F 62 Kidney 3/14/83 4.5 55.4 
4 Regression M 15 Kidney 1/6/85 6." 31.3 
5 Regression M 3 Uver 8{7184 11.2 31.6 
6 Regression M 7 Liver 816/84 7.8 11 35.0 
7 RegresSlOll M 1 Liver 4/4185 11.7 23.1 
8 Regression M 2 Uver 4110/86 2.3 20.1 
9 Regression M 43 Uver 2125/86 4.4 19.5 
10 Regress!OOlresolutiont M 16 Kidney 12112/82 3.5 59,4 
11 Resolution M 30 Heart 10/22/84 3.3 36.9 
12 Resolution M 56 Hear1 1119/85 3.1 34.2 
13 Resolution M 22 Heart/lung 5/25/83 2.1 17.0 
14 Resolution F 25 Kidney 1/31180 5.3 9~K4 
15 Resolution M 20 Kidney 4/15/81 6.1 n.O 
16 Resolution M 52 Kidney 8/23/81 12.2 66.6 
17 Resolution M 56 Kidney 2/10182 6.2 66.9 
18 Resolution M 30 Kidney 7/10/82 4.5 63.5 
19 Resolution M 11 Kidney 513/85 13.7 20.1 
20 Resolution M 23 Kidney 8/15/86 2.2 16.0 
21 Resolution M 17 Liver 5/9/82 6.1 84.0 
22 Resolution F 21 Liver 3120183 6.7 52.9 
23 Resolution F 3 Uver 5/10/84 2.6 43.2 
24 Resolution M 9 Liver 9/3185 2.9 26.8 
25 Resolution F 44 Liver 10/4/86 1.1 2.9 
26 Resolution F 3 Uver 5/5/85 22.7 11.0 
27 Partial resolution M 22 Heart 11/11/81 6.1 5.6 
28 Partial resolution F 13 Uver 8/31{77 68.3 4.8 
29 Resolution M 4 Liver 1/14/84 25.1 3 24.5 
30 No evaluable response M 34 Kidney 2127/86 1.5 0.5 
31 No evaluable response M 20 Liver 1/12/82 7.5 15.9 
32 No evaluable response F 1.5 Liver 2120{72 162.0 0.1 
33 No response M 20 Hear1/lung 1/31183 3.8 1.0 
34 No response F 8 Liver 1111/82 26.2 24 13.3 
35 No response M 5 Uver 12117185 0.7 1.2 
36 No response M 54 Uver 8118/86 12 0.3 
37 No response F 27 Uver 2/26/86 12.1 0.2 
38 Autopsy diagnosis only M 51 Heart 9{27/82 6.6 
39 Autopsy diagnosis only M 28 Kidney 219/80 4.0 
40 Autopsy diagnosis only F 11 Liver 9/19185 1.9 
41 Autopsy diagnosiS only F 4 Uver 8/22185 4.0 
42 Autopsy diagnosis only F 26 Liver 911/83 4.3 
43 Autopsy diagnosis only M 23 Liver 10/30/83 1.8 
• See Materials and Methods section. 
t Some IlMnOrS resected. others allowed to regress. 
1.7Cf in this patient series. This figure may underesti- rate at the authors' institution is about 50%. No pat-
mate the true incidence of the disorder since some tern ofincreasing or decreasing rate ofPTLD develop-
cases are first recognized at autopsy. and the autopsy ment has been apparent to date. The years 1980-1982 
were marked by a predominance of tumor develop-
Table 2-lmmunosuppressive Regimens of 43 PTLD Patients ment in renal transplant recipients. From 1983 to 
Drug regimen Number 
date. the majority ofIesions have occurred within be-
patic allograft recipients. This relative rise appears di-
CsA.prednisone 21 rectly related to the increasing number of liver trans-
CsA.prednisone + OKT3 9 plants performed at this Center. CsA-prednisone + azathioprine 4 
CsA-prednisone + AlG 3 
CsA-prednisone + azathioprine + OKT3 3 Immunosuppressive protocols (fable 2) CsA-prednisone + azathioprine + ALG 2 
CsA-prednisone + TOO Forty-one of the 43 patients received initial immu-
ALG. antilymphocyteglobuin; TOO, Ihoracicductdrainage. nosuppression based on the use of CSA-prednisone 
._ I» • 1'10 I 
emaining two (No. 28 and 32) received CsA 
aJ!d t~et~eir course. One patient who underwent liver 
"fcrt~anl in 1977 received azath.ioprine ~nd predni-
ll'1lnsP initial immunosuppressIOn. This was later 
~Fne ::d to CsA-prednison~K A. second. patient w~o 
~~flD nsplanted in 1972 likewise received azathlO-
1f~ ;~nd prednisone and was s""itched to CsA-pred-
pnn ne in mid 1984. 
111~ 'cntv-one patients received CSA-prednisone as ~ Ie immunosuppressive agents. The remainder fh~~ed various combin.ations of OKT3, azathio-
I"CI:: e anti-lymphocyte globulin or thoracic duct 
pnn • . d' T bl 2 drainage as summanze In a e . 
lime to Tumor Onset (Table 1) 
The time interval between organ allograft an~ tu-
or diagnosis ranged from 0.7 to 162 months With a 
m can of 11.5 and a median of 4.5 months. Of note, ~~ twO patients who were initially immunosup-~rcssed with azathioprine-containing regimens had 
lurnor diagnosed at 68.3 and 162.0 months after 
lransplant. If these two patients are excluded from the 
analysis. the range of time intervals from transplant 
10 lumor diagnosis in individuals initially immuno-
suppressed with CsA-prednisone regimens is 0.7-26.2 
months with a mean time interval of 6.4 ± 1.0 and a 
median of 4.4 months. No difference in time interval 
was seen in those patients initially immunosuppressed 
wilh CsA who later received supplemental azathio-
prine. Likewise. no difference in onset time could be 
documented for those subsets of patients receiving ei-
Ihersupplemental OKT3 or ALG. 
Clinical Presentation (Table 3) 
The clinical presentation of PTLD reflected a com-
hination of constitutional symptoms. effects related to 
the sites oflymphocyte proliferation. and the presence 
or absence of concomitant infectious disease. The 
clinical presentations and their categorizations are 
presented in Table 3. 
The 43 patients were categorized according to the 
predominant site of symptoms. Thirteen patients had 
signs and symptoms referable to the head and neck 
region. The most common form of presentation 
within this category was a mononucleosislike syn-
drome with fever. adenopathy. tonsillitis, and sore 
Ihroat. A 14th patient presented with rectal bleeding 
in addition to a cervical mass. Especially in children, 
adenotonsillitis could lead to acute and life-threaten-
ing airway obstruction that requires urgent interven-
tion for relief. 
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Twelve patients had abdominal disease, with signs 
and symptoms of gastrointestinal involvement in II 
of 12 cases. Fever and pain together with bowel perfo-
ration were the most common symptoms in this pa-
tient subset. One of these patients (No. 17) had, in ad-
dition to bowel perforation, prostatic obstruction that 
was also due to tumor. Another patient had a cervical 
mass in addition to rectal bleeding. The 12th patient 
(No.5) had feyer, anorexia, and vague abdominal 
pain suggestive of a mononucleosislike syndrome. 
Ten patients had signs or symptoms suggestive of 
organ dysfunction. In five patients the presentation 
suggested liver involvement (No. 24, 25, 32, 36, 37). 
One of these patients (No. 32) had jaundice in associa-
tion with a mononucleosislike syndrome. It is note-
worthy that all of these patients were liver transplant 
recipients. Three additional patients (No. 20, 28, 30) 
had a clinical presentation of renal dysfunction. Two 
other patients (No.2, 9) presented with evidence of 
pulmonary disorders. In one case this manifested as 
pneumothorax; in the other, as non resolving nodular 
lung infiltrates after successful treatment of Pneumo-
cystis pneumonia. 
Two patients presented with other signs and symp-
toms. In one (No. I), inguinal adenopathy was the ini-
tial finding. In the other E~oK 34), weight loss, fever, 
and anorexia were noted. 
The diagnosis of PTLD was first made at autopsy 
in six patients (No. 38-43). The final clinical presenta-
tions of these patients are tabulated in Table 3. 
Associated infections (Table 4) 
EBV 
Specific studies regarding the virologic aspects of 
this disorder have been presented previously.13 Based 
on serologic analysis, forty of the 43 patients had evi-
dence of EBV infection. Twenty-eight patients had 
primary EBV infection, 12 had secondary infection, 
and 3 had past infection at the time that PTLD was 
diagnosed. 
Not surprisingly, primary infection was more com-
mon in the younger age category. Ninety-four percent 
(17 of 18 cases) of pediatric cases demonstrated evi-
dence of primary infection. In contrast, primary infec-
tions were seen in 42% of patients aged 18 years or 
older. Only I of 12 cases of reactivation infection oc-
curred in the pediatric population. 
Each of the patients "'ith initial immunosuppres-
sive therapy consisting of azathioprine regimens and 
tumor onset after an extended time interval also had 
evidence of primary EBV infection. 
-
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Table 4-Epstein-Barr Virus and Other Infections 
in PTLD Patients 
Infection 
Patient no. type Other infections 
Regression 
1 Secondary Gastroenteritis 
2 Primary None 
3 Primary Herpes simplex 
4 Primary None 
5 Primary None 
6 Primary None 
7 Primary? None 
8 Primary None 
9 Past Pneumocystis, CMV 
10 Primary None 
Resolution 
11 Primary Pneumocystis 
12 Primary Pneumocystis 
13 Primary CMV 
14 Primary None 
15 Secondary None 
16 Past Herpes simplex 
17 Secondary None 
18 Secondary Herpes simplex 
19 Primary None 
20 Primary None 
21 Primary None 
22 Secondary Fungal pneumonia, cholangitis 
23 Primary None 
24 Primary Hepatic enterococcus infection 
25 Secondary Herpes simplex 
26 Primary None 
27 Primary Pneumonia. (later sepsis) 
28 Secondary None 
29 Primary None 
NER 
30 Primary CMV, Aspergillus, Pseudomonas 
31 Secondary None 
32 Primary None 
NR 
33 Primary Cryptococcosis 
34 Primary Invasive aspergillosis 
35 Primary None 
36 Secondary None 
37 Secondary Herpes simplex 
A 
38 Secondary CMV pneumonia. (aspergillus 
brain abscess at post) 
39 Secondary Pneumocystis 
40 Primary CMV, Candidiasis 
41 Primary Pneumocystis 
42 Past Pneumocystis, Candidiasis 
43 Primary CMV. Pseudomonas sepsis 
PR, partial resolution; Re. recurrence; NER, no evaluable re-
sponse; NR. no response; A, autopsy diagnosis. . 
Other infections 
Approximately half of the patients had contempo-
raneous infections at the time of PTLD diagnosis. 
Pneumocystis carinii was found in six patients; five 
patients each had herpes simplex or cytomegalovirus 
infections. Infection was identified as the main cause 
of death in six patients. 
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Pathologic Features of Lesions 
Gross Pathology 
~:"of!·v 
K"~: 
PTLDs may assume one of three general gross ap.-
pearances: a solid tumor. a diffuse infiltrate of paren. 
chymal organ, or enlargement of native lymphoid 
tissue. 
Tumorous PTLDs are indistinguishable from lym. 
phoma at a macroscopic level. The lesions appear 
gray-white, have a vaguely lobulated appearance, and 
often contain extensive areas of necrosis. The total tu-' 
mar bulk can be considerable due to multicentricity _ 
and the large size (up to [5 cm) of individual tumors. ... -
The appearance of tumors may be modified when" 
they occur in the gastrointestinal tract (Figure lFK~ 
These lesions freely ulcerate the mucosa and penetrate" 
the muscularis propria. This can lead to frank perfora-~ 
tion and subsequent peritoneal implants. In mose' 
cases the mucosal aspect presents an ulceronodularc ;, 
appearance with an overlying green-yellow pseudo--
membrane. 
Infiltration of organs may be inapparent at a grOSS 
level, or may lead to a mottled appearance. In several-' 
cases kidneys containing PTLD were thought at the 
time of surgery to have an appearance consistent with 
severe rejection. 
Microscopic Pathology (Table 5) 
The microscopic appearance of PTLD is that of a . 
diffuse proliferation of lymphoid cells that may be 
characterized on the basis of the degree oflymphocyte 
heterogeneity. 
In most cases, the entire range of recognizable B 
lymphocyte forms is seen. Such lesions contain vary-
ing proportions of small lymphocytes, small and large 
cleaved and noncleaved lymphocytes, immunoblasts, 
plasmacytoid and plasma cells. This type of polymor-
phic appearance was seen in 47 of 83 histologically 
evaluable specimens (Table 5, Figure 2A). 
Monomorphic PTLDs are composed of uniform 
lymphoid cells overwhelmingly at one stage of differ-
entiation. most commonly represented by a prolifera-
tion of either small or large noncleaved lymphocytes. 
Plasmacellular differentiation is in general not a fea-
ture of such lesions and the appearance is indis-
tinguishable from that of typical non-Hodgkin's 
lymphomas. The histologic categorization of mono-
morphic PTLD was applied to 12 of 83 specimens 
(Figure 2B). 
In occasional lesions, the degree of polymorphism 
was considered to be slight because most of the cells 
appeared to be in the latter stages of the B cell differ-
entiation pathway (ie, plasma cells and plasmacytoid 
.,. Ill. !lio I 
Such PTLDs were categorized as displa~ing 
(ellS) .. al pohmorphism" (Table 5). Twenty-four of 
"!Il IOI(l1' h H 
'imens showed suc an appearance, owe\"er. 
U~ :r;hese 2-t specimens were derived from a single 
I . I (patient 10. Table 5). ~t~nI ' 
'IIecrosis. which may be ~asslveK comm~nly occurs 
"de confluent swaths (Figure 3). Reactive neutro-
111 \II I . . 
I and histiocy1es are common y seen In assocla-phi S 'N' be . (" \lith necrosIS. , ecrosls may seen In any lorm 
tf~F~·fiaK but in the authors' experience tends to be 
~lpf pronounce.d in th~ po~:mMD:mhic .form. ., 
Cells compatible wf~hD ~typl~al lf~munoblaRts 
re seen infrequently In thiS senes (Figure 4). They 
,,( ded to occur in polymorphic PTLDs, especially 
It'" . 0 I . f ar areas of necrosIs. n y one specimen 0 mone-
:orphiC PTLD contained rare cells categorized as 
I\'pical immunoblasts. 
a 'Exlranodal PTLDs manifested as either infiltrative 
Ir tumorous processes. Infiltrative PTLDs occurred in 
:he interstitium of various organs and appeared either 
as discrete foci or as coalescent areas of Iymphoidl 
plasEl1aC~1Mid cells. With small infiltrates, destruction 
(If the underlying organ was inapparent or absent. 
Larger infiltrates merged imperceptibly with tumor-
ous lesions on both a gross and microscopic level. 
Secondary changes were dependent on the organ in-
wived. In the gut. the mucosal surface sustained early 
Jnd marked necrosis. In larger lesions the mucosa was 
ulcerated and inhabited by innumerable bacteria. 
Solid organs could show marked parenchymal neere-
~fp in addition to tumor necrosis. Occasionally. the ex-
Icnt of parenchymal necrosis overshadowed lym-
phoid necrosis. especially if the PTLD was of the in-
tiltrative type. Such disproportionate organ injury was 
~Dcn particularly in the liver. 
In rare cases a benign-appearing, reactive diffuse 
plasmacytic hyperplasia was seen in lymph nodes in 
lases that had concurrent or subsequent PTLD else-
"here. This hyperplasia, which technically can be 
classified as showing minimal polymorphism accord-
ing to the present classification system. is associated 
with retention of underlying architecture (Figure 5). 
Its relationship to PTLD is undefined at present. 
.Inal.rsis qfTlIIl10r Clonalil,l' (Table 5) 
Immunophenotypic studies were performed on 70 
specimens from 34 patients. as outlined in Table 5. 
C)10plasmic immunoglobulins were visualized in 
many but not all cases containing an obvious plasma-
c)1oid or large cell component. Presumptive determi-
nation of clonality was based on immunoglobulin 
light-chain ratios as outlined in the Material and 
Methods section. A conclusion regarding c10nality 
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was reached in 44 specimens; in the other 26 the re-
sults were inconclusive. 
Immunoglobulin gene rearrangement studies were 
performed in 30 tissue specimens from 20 cases. A 
representative series is demonstrated in Figure 6. 
As expected. immunogenotypic analysis provided a 
more sensitive indicator of c10nality than did immu-
nophenotypic analysis. Twenty-one specimens from 
18 patients were studied by both methods (Table 5). 
Identical conclusions were reached in II specimens. 
In seven other specimens, DNA analysis gave conclu-
sive results whereas immunophenotypic analysis was 
indeterminate. Only in three specimens from cases 5, 
6. and 28 was a discrepancy between the two tech-
niques observed. In each case, DNA analysis detected 
a monoclonal component that had been missed by 
immunocytochemical means. In seven specimens 
that were monoclonal by immunocytochemical anal-
ysis and in which DNA analysis was performed, how-
ever. the diagnosis of monoclonality was upheld in ev-
ery instance. 
These results so far indicate that. of the 43 patients, 
12 had monoclonal lesions, 13 had polyclonallesions, 
and 5 had separate monoclonal and polyclonal le-
sions. No conclusions regarding clonality have yet 
been reached on tissues from the other 13 patients. 
In those cases in which genotypic clonality was de-
termined, it was possible to make a semiquantitative 
estimate of the proportion of cells that demonstrated 
the clonal rearrangement, which was termed "clone 
strength." A value of 3+ indicates a rearranged band 
equal to or more intense than the main germline 
band; 2+ indicates a strong rearranged band, weaker 
than the germline band. I + indicates a weak band. 
and 0 indicates that no gene rearrangement was de-
tected. Because the region detected by the JH probe is 
split by heavy chain gene rearrangements. the hybrid-
ization band from the rearranged gene will be weaker 
than the band from the nonrearranged gene. A I + 
clone strength could thus represent a significant un-
derestimate if only a JH probe is used. A representa-
tive determination is demonstrated in Figure 6. Re-
sults are tabulated on Table 5. 
Conclusions regarding histologic appearance and 
c10nality were available for 58 specimens. Thirty-one 
such specimens had a polymorphic histology. Of 
these. 17 were polycJonal and 14 were monoclonal. 
Of22 specimens with minimal polymorphism, 4 were 
polyclonal and 18 were clonal. Finally, all five evalu-
able monomorphic PTLDs were monoclonal. 
Lymph nodes that showed a diffuse reactive plas-
macytic histology and were associated with PTLD 
elsewhere were invariably polycJonai. 
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184 NALESNIK IT AL 
Evalualion of MU/lip/e Specimens from Individual 
PatienlS 
More than one specimen was obtained in 15 of 43 
patients. Some features of interest are noted here. 
Patient to underwent resection of multiple gastro-
intestinal tumors. Some of these minimally polymor-
phic lesions were monoclonal and others were poly-
clonal by immunophenotype. Gonal tumors demon-
strated cytoplasmic kappa:lambda ratios ranging 
from 3.3:1 to 116:1. One representative lymph node 
was shown to have a polyclonal pattern. A tumor im-
plant in the mesenteric fat contained lambda-contain-
ing and kappa-containing cells (intracytoplasmic) in a 
ratio of92: I. 
Not all tumors were removed at that time. The pa-
tient's immunosuppression was discontinued over a 
5-week period, during which time he rejected his allo-
graft. At the time of allograft nephrectomy, an at-
tempt was made to remove residual tumors. However, 
it was observed that the lesions had either shrunken 
drastically in size or had disappeared completely. A 
resected length of bowel demonstrated several lesions 
composed predominantly of mature plasma cells in 
association with bowel wall repair. Cytoplasmic im-
munoglobulin stains of three lesions demonstrated cy-
toplasmic lambda:kappa ratios of 3.8: I, 25: I, and 60: 
I. A resected lymph node was nonclonal. 
Patient 34 had a polymorphic PTLD in December 
1984. She continued to have recurrent viral episodes 
over the following year and in 1986 presented with 
a widespread monomorphic tumor. This lesion was 
unresponsive to belated modulation of immunosup-
pression. Infectious complications in association with 
the tumor led to the patient's demise. 
AlP • October 1911 
Figure 1-0ne of many large IfItestlnaJ tUrT'oClrS 
resected from patient 10, The bowet wall has 
been opened longitudinally and the ulcel'onodu-
lar tumor is viewed from the mucosal aspect. , 
Both monoclonal and poIydonallesions were do 
agnosed, Several tumors were not resected and 
were observed to undergo regression during a 
several week period of withdrawal of mm~ 
suppression. The patient remains free of tumor 
55 months after diagnosis, 
Patient 29 had a monomorphic tumor on several 
occasions. Temporary remission was obtained by sur-
gical resections, only to have an identical-appearing 
tumor recur. This tumor was unresponsive to modu-
lation of immunosuppression. The patient is cur-
rently alive with tumor. 
Recurrence of a polymorphic PTLD also occurred 
in patient 6, who remains well to date with no further 
evidence of disease. The recurrence resolved under 
the influence of surgery and reduced immunosuppres-
sion. 
Oinicopathologic Correlation 
Clinical Presentation and EXlent of Tumor 
The manner of presentation of an individual pa-
tient offered a reasonable guide to the location of the 
pathologic process. Of the 12 patients who had gastro-
intestinal/abdominal complaints, II were subse-
quently shown to have mass lesions involving the gas-
trointestinal tract. The 12th patient in this category, 
who had more constitutional symptoms, had enlarged 
retroperitoneal nodes in addition to involvement of 
the tonsillar and cervical region. 
Likewise, the 13 patients who had symptoms refera-
ble to the head and neck regions had PTLD located 
predominantly located at these sites. The same situa-
tion obtained in the ten patients who had evidence of 
organ dysfunction. A separate patient who initially 
had ileum perforation, was also found to have pros-
tate obstruction (17). Subsequent biopsy revealed 
widespread involvement of this organ by tumor. 
Although the clinical presentation is useful in local-
izing the major sites of PTLD, it does not necessarily 
• 
val Ill' :'<0. I 
. re 2A_Representative pleomOrphic (poIy-~fCF proliferation !rom patient 23. Lympno. 
es at all stages of differentiation are present ~a diffuse pattern. A smaD area of necrosis is 
tee<l1l1 the lOwer nght comer H & E. onglnaJ 
I1119"'foeatlon x312. 
define the extent of the disease. Patients 30 and 32-
36 indicate this. Because prospective staging was not 
uniformly performed in these patients, the true patho-
logic extent of PTLD in this population can only be 
approximated. 
A gastrointestinal/abdominal presentation is ass0-
ciated with a good prognostic outcome at our institu-
tion. Ten of 12 patients with this presentation are 
alive with follow-up times ranging from 20 to 88 
months. Only one patient in this group had recur-
rence of tumor. The two patients who died (No. 33, 
35), did so 1 month after diagnosis and had tumors at 
multiple sites at autopsy. 
Ten of 13 patients with a head and neck site also 
are alive at time intervals ranging from 7 to 62 months 
following diagnosis. Recurrence was seen in only one 
patient. One of the three deaths in this group was due 
to unrelated causes 17 months after diagnosis. No tu-
morwas found at autopsy (No. 13). In another patient 
(No. 27), tumor was eradicated by chemotherapy, but 
death supervened due to sepsis. Finally, a third patient 
CsA TRANSPLANT L HfPHOMAS 185 
(No. 31) died of laryngospasm following an ENT 
exam. 
Presentation with organ dysfunction was not ass0-
ciated with a similar high survival rate. Four of 10 pa-
tients in this category are alive from 9-23 months af-
ter diagnosis. In each survivor, tumor was apparently 
restricted to the individual symptomatic organ, some-
times involving its contiguous lymph nodes. In con-
trast, nonsurvivors were generally found to have tu-
mor at sites well-removed from the organ of presenta-
tion. 
Relation o/Clonal Status to Onset Time 
Of the patients initially immunosuppressed with 
CsA, there was no apparent difference in time dura-
tion between transplant and tumor diagnosis, regard-
less of whether the lesion was clonal or nonclonal. The 
median time of onset in patients with non-clonalle-
sions was 4.4 months (range, 1.1-26.2), and in pa-
tients with clonal lesions this value was 4.1 months 
(range, 0.7-25.1). 
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Response to Therapy 
Clinicat regression of PTLD was seen in ten patients 
who received therapeutic intervention based on a re-
duction of immunosuppression (No. 1-10). Two pa-
tients received acyclovir and one patient had ad-
ditional resection, which demonstrated involuting 
monoclonal tumor. Most of the tumors had a poly-
morphic appearance with mild to extensive necrosis. 
Within this group, two patients had clonal tumors, 
two had clonal and nondonal tumors, three had non-
clonal lesions. and in three the c10nality was indeter-
minate. In those cases in which an estimate of the rela-
tive proportion of cells with a rearranged phenotype 
was possible (band strength, Table I), it was found to 
be low in comparison with control non-Hodgkin's 
lymphomas. 
Nineteen patients (No. 11-29) had resolution oftu-
mor. Of these 19, only four received chemotherapy or 
radiotherapy. The remainder were treated with re-
duced immunosuppression coupled with surgical re-
section of grossly visible tumor. The histologic and 
FIgure 2B-Monomorphic proliferation from 
patient 29. Lymphoid cells are all at the sarna 
stage of development The only heterClgenejty 
10 appearance IS provided by mitotic figI.na, 
macrophages and individual necrotic eels. H & 
E, original magnification x312. 
clonal characteristics of these tumors were in general 
similar to those of the first group. As a whole, gross 
disease was more advanced in this group of 17 pa-
tients, This accounted for the more aggressive surgical 
intervention (Table 3). . 
No response to therapy was seen in five patients 
(No. 33-37). All five patients had disease at more than 
one site. and usually at multiple sites (Table 3). Oonal 
analysis was performed in four patients and demon-
strated clonal rearrangements in every case. The in-
tensity of the rearranged bands in this group was 
much stronger than in those cases which had under-
gone regression. 
One patient (No. 29) had several instances of recur-
rent disease. This patient had a large but well-circum-
scribed involvement of the abdomen by a monomor-
phic clonal tumor. 
Six patients received a diagnosis of PTLD at au-
topsy (No. 39-44), precluding comment on clinical 
behavior. These patients had in common the presence 
of multiple, severe, opportunistic infections (Table 4~ 
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F"9I" 3-Extensive necrosis appears as amorphous areas in this Iow-power photomicrograph. H & E. original rnagMication x50. 
F'ogure 4-large atypical blaSt ("atypical imfnu. 
noIJjast") from patient 18. The multilobed nu-
deus is partially out of the plane of section due 
10 rts large volume. Portions of several nucleoli 
Ire also observecI within this oeI. The back· 
g:ound cells demonstrate a minimal degree of 
;dymorphism due to a preponderance of pIas. 
macytoid forms. H & E. original magnification 
'500. 
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Tumor was found in more than one site in each case 
(Table 3). 
Discussion 
The 43 allograft patients described in this report de-
veloped posttransplant lymphoproliferative disorders 
in conjunction with CsA-containing immunosup-
pressive regimens. The overall tumor incidence of 
1.7% is in close agreement \\<ith figures derived from 
non-CsA immunosuppressed transplant popula-
tions. ls and indicates that immunosuppression per se 
is the common denominator in these cases. 
Minor differences of tumor frequency exist among 
the various organ allograft subpopulations in our se-
AJP • 0c'IDber I", 
F"lgure SA-Low power photomicrograph of • 
lymph node from patient 31. The diffuse natl.n 
of the proliferation. the "starry sky" appear. 
ance. and the preservation of sinusoids are _ 
apparent in this Iow-power photom~ 
The lesion was diagnosed as reactive h~ 
sia and the patient represented several ~ 
later with more typical PTLD. H & E. ongn., 
magnification x50. B-Higher magrWfic:a.. 
tion of A. Severaliarge macropllages are SII. 
rounded by smaller mature plasma cells. The I&-
sion appears histologically benign. HoweYw. 
the diffuse plasmacefluiar infiltrate s/loukj SU9-
gest the possibility of early PTLD or the pres. 
ence of PTLD elsewhere and prompt a SewctI 
for EBV infection. Reduction of ~
pression at this stage wi" almost invariably be 
associated with clinical remission. 
ries. however. Kidney recIpIents have the lowest 
(1.0%) and heart/lung recipients the highest (4.6,*) 
rate of PTLD in this population. Although these 
differences are most likely due to differing intensities 
of immunosuppression in the various subpopula-
tions, the authors wish to stress the low incidence 
in heart/lung recipients in contrast to previous esti-
mates (8). 
A major difference between PTLDs arising in CsA-
immunosuppressed and conventionally immunosup-
pressed patients relates to the time of onset. The me-
dian time interval between transplant and tumor in 
patients initially immunosuppressed with CsA is 4.4 
months in this series. Two of the 43 patients who re-
ceived azathioprine but not CsA as part of the initial 
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rlgure 6-lmmunoglobulin heavy chain gene analysis. Five micr~ (Of less) of each DNA was digested with Bam HI, resolved on an 0.7% agarose gel, 
!*)ned to nitrocellulose. and hytlridized 10 7.5 X 10" d/min/m of P-labeled J" probe. Detailed hybridization protocols have been described. Control DNAs 
were obtained from normal liver and hyperplastic tonsil. Both showed one prominent and two Ight germIine blinds (G). The tonsi specimen also showed a 
blur beneath the main germline band, caused by nondonaJ gene rearrangements. This blur is characteristic of reactive B eel populations. Individual patients 
are designated A-H. Two separate tumors from patient 0 were analyzed. The DNA from patient C's tumor shows a weak gennIine band, suggesting deletion 
of tile nonrearranged heavy chain gene. 
immunosuppression had significantly longer intervals 
to tumor development, This phenomenon has been 
observed by others,ls The underlying pathophysio-
logic mechanisms of this difference are obscure. 
Presentation of PTLD falls into several general cat-
egories. Patients presenting with localized symptom-
atology demonstrate predominant involvement of the 
head and neck, gastrointestinal tract, or solid organ. 
Head and neck disease may range from a syndrome 
indistinguishable from infectious mononucleosis to a 
localized tumor mass. It is likely that some cases in-
cluded in this category do indeed represent infectious 
mononucleosis. Because only a portion of transplant 
patients with active Epstein-Barr virus infection ever 
receive the generic diagnosis of "posttransplant Iym-
phoproliferative syndrome," many probably have 
subclinical disease that resolves despite continued im-
munosuppression. The detection of a clonal rear-
rangement in at least one patients with a presentation 
otherwise consistent v.;th infectious mononucleosis 
suggests caution in this regard, however. 
There appears to be an affinity of PTLD for the allo-
graft organ in cases of isolated organ involvement. It 
has been suggested that continued antigenic stimula-
tion may play a role in facilitating development of 
these lesions. While the present study sheds no further 
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light on this topic, it does point out to the pathologist 
that this lesion must always be considered in the histo-
logic differential diagnosis of organ allograft rejection. 
The association of PTLD with Epstein-Barr virus 
infection. alluded to above. has been repeatedly 
stressed. The present series aglin emphasizes this rela-
tionship. More detailed analysis of the role of EBV in 
this transplant population is provided by Ho et al.30 
Posttransplant lymphoproliferative tumors may be 
single or multiple lesions. It is important to realize 
that, in the case of multiple tumors, some masses may 
represent clonal proliferations, whereas other, concur-
rent lesions may represent nonclonal growths. Fur-
ther, multiple clonal proliferations mayor may not 
show identical immunoglobulin gene rearrangement 
patterns. The presence of an identical gene rearrange-
ment pattern in more than one tumor is strong evi-
dence in support of a metastatic process. In those cases 
in which noncontiguous clonal tumors demonstrate 
unique gene rearrangement patterns, the conclusion 
is not as clear. This result may be due to the presence 
of multiple independent primary tumors. Alterna-
tively, it may represent continuing gene rearrange-
ments within tumors that have evolved from a 
progenitor clone. 19 Preliminary studies from this 
. laboratory, using a DNA probe unrelated to the 
immunoglobulin genes, have suggested that at least 
some patients have multiple clonal tumors as the re-
sult of the latter mechanism (Locker J., et al, in prepa-
ration). 
Presentation with mUltiple tumors has been ob-
served in other series. 12.19 The most notable cases of 
multiple EBV-associated posttransplant lymphopro-
liferative tumor presentation was that of the "bubble 
boy",27 who developed this disease after receiving a T 
cell depleted histioincompatible bone marrow trans-
plant. There are striking similarities between that case 
and some cases within the present series, including the 
presence of concurrent clonal and noncJonal tumors, 
numerous (>20) colonic lesions, and a polymorphic 
lymphoid tumor histology. In that case the authors 
demonstrated that some of the phenotypically poly-
clonal proliferations were genotypically oligoclonal, 
and one had a monoclonal component. They logically 
suggested a progression sequence in which a mono-
clonal tumor evolved from a polyclonal background. 
In typical infectious mononucleosis in the nonim-
munosuppressed individual, the B lymphocyte prolif-
eration is polyclonal. 28 However, Brichacek et aI, ana-
lyzing DNA from tissues of patients with fatal infec-
tious mononUcleosis, found several examples of 
clonal B cell proliferative infiltrates in their cases.29 Of 
further interest, all of their specimens were obtained 
'" . --f" '" ~ ... 
from patients who died within 1-20 weeks of syn{J.. ,od 1= 
tom onset. Thus. the results indicate that the el1lct. lCar· 
gence of clonal proliferations may occur early in casei .-euti( 
of fatal infectious mononucleosis. The early ernet:: umo' 
gence of monoclonal lesions is also a feature of thex)iyr. 
present series, as noted above. :ump 
Perhaps the most controversial aspect of these Ie- g~atr 
sions relates to claims of tumor regression under~ 1l0rs 
tablished host immune controls. This report exDallds :~tic 
the initial observation of this behavior and also serves It i~ 
to set an upper limit on this phenomenon. ~ ,ant' 
A previous histopathologic classification of PlLD rn m L 
was proposed by Frizzera7 on the basis of the ~ let in 
sota transplant population. That group suggeste<fi :umc 
progression from "polymorphic diffuse B cell bvnf):· lod r. 
plasia" to "polymorphic diffuse B cell lymph~~ :ardl, 
(PBL) based on the presence of necrosiS and atypicij 5 1m: 
immunoblasts in the latter category. The designati&a·mal· 
of PBL was used to indicate a malignancy arising frOiD qh~ 
a reactive background. With the diminution aDd -ctair. 
eventual disappearance of follicular center cells the Jo. :\01\ 
sion would be diagnosed as an immunoblastic~K ;ions 
coma. ~ :nan:: 
In the authors' experience, necrosis and atypiCll eow~ 
immunoblasts do not serve as a correlate ofmaligna'ji :ypic 
transformation in these lesions. Rather, the directioD PTU 
of malignant progression, in a general sense, appea'iJ \\'ho 
to ?e f~om a pof~morphic to a monomorphic histq; jespi 
lOgIC pIcture. ThIs pathway corresponds to some dO, ~Dhat 
gree with the distribution of clonal (monoclonal) aDd h' : IS r. 
nondonal (polyclonal) lesions. That is, nonclo~ [he r 
proliferations appear polymorphic and donal proS [lene' 
erations appear either polymorphic or monomorphic. ;lriCI. 
The authors have not observed this theoretical path-
way of polymorphic to monomorphic evolution tooc-
cur in any individual lesion in this series, a POint 
h . I. P wort stressmg. I~K 
These results indicate that nonclonal PTLDs and a 2. F, 
subpopulation of clonal PTLDs are both capable of r 
regression following reduced immunosuppression. 
Widespread clonal PTLDs do not respond in the same 
manner and can rapidly cause the death of the host. 
c 
L 
Most of the cases of widespread tumor in this series 3. 5 
c 
also were notable for delays in diagnosis, often with 
elevated immunosuppression during these delays. It is 
impossible to draw conclusions regarding the relative 4. F' 
roles of intrinsic tumor nonresponsiveness to bost 5. \ 
control mechanisms versus massive tumor burden 
leading to host unresponsiveness in such cases. It is 
likely that some cases fall into either category. A hiab _ 
level of clinical suspicion may serve to reduce the 00. 6.' 
currence of such widespread cases in the future. In t6i,:: 
interim, it is observed that po,ymO<PhiC/po'1., 
:r:K~KKI ... : 
.,01 IJ.' • " .... ! 
d pol~ morphic monoclonal tumors in general ap-
P~ar to ~ more responsive to a conservative thera-
pt: utic r~imen than do monomorphic/monoclonal 
~morsK \fonoclonal tumors t~at are "minimally 
hnlOrphic", Ie, have a predommant plasmacellular 
pO ~pon~ni also appear to be more responsive to 
\'O.atment than do monomorphic/monoclonal tu-
~tors that have essentially no evidence of a plasma-
.,tic component. 
"It is difficult at this point to clearly separate "malig-
ant" from "nonmalignan(' PTLDs. Clearly, in the nmmun~uppressed host. many of these lesions will 
I ct in a malignant fashion, In particular, monoclonal 
:umors that are capable of invasion, tissue destruction 
3nd metaStasis should be considered malignant re-
Wdless of subseq uent demonstration of regression, It 
is important to mentally dissociate the concepts of 
"malignancy" and "regression" in these tumors. 
That only a subpopulation of monoclonal lesions 
retain th~ capability of regression may point to rapidly 
(\olving tumor progression in this category of le-
sions.3u: Karyotypic analysis was not performed in 
many of these cases and is not reported in this study. 
However. Hanto et alII have reported clonal karyo-
typic abnormalities in several of their patients with 
PTLD. They noted regression of tumor in one patient 
who received CsA-containing immunosuppression, 
despite the presence of karyotypic abnormalities. To 
IIhat degree the host and tumor each contribute to 
this neoplastic progression remains to be investigated. 
The results of investigations of this system may have 
benefits well beyond those applicable to this highly re-
stricted group of patients. 
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